Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AZD 3293 is an inhibitor of β-secretase 1 (BACE1) and BACE2 (Kis = 0.4 and 0.8 nM, respectively).1 It is selective for BACE1 and BACE2 over cathepsin D, γ-secretase, and human-ether-a-go-go (hERG; IC50s = 3,797, >25,000, and 4,700 nM, respectively). AZD 3293 inhibits the secretion of amyloid-β (1-40) (Aβ40) in primary mouse and guinea pig neuronal cultures (IC50s = 0.61 and 0.31 NM, respectively), as well as in SH-SY5Y cells overexpressing human amyloid precursor protein (APP; IC50 = 0.08 nM). In vivo, AZD 3293 (50, 100, and 200 µmol/kg) reduces plasma and brain levels of Aβ40 and brain levels of Aβ42 in mice.
WARNING This product is not for human or veterinary use.
1. AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-